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Abstract
Background: Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) approved
for the treatment of advanced non-small cell lung cancer (NSCLC). Few treatment options are available for NSCLC
patients who have responded to gefitinib treatment and demonstrated tumor progression. The present study was
conducted to evaluate the efficacy and toxicity of the 2
nd EGFR-TKI administration.
Methods: We retrospectively analyzed 11 patients who had obtained a partial response (PR) or stable disease (SD)
with gefitinib treatment and were re-treated with EGFR-TKI after failure of the initial gefitinib treatment.
Results: Three patients (27%) were treated with gefitinib as the 2
nd EGFR-TKI, and 8 patients (73%) received
erlotinib. Only one patient (9%) showed PR, 7 (64%) achieved SD, and 3 (27%) had progressive disease. The disease
control rate was 73% (95% CI, 43% - 91%) and the median progression-free survival was 3.4 months (95% CI,
2 - 5.2). The median overall survival from the beginning of the 2
nd EGFR-TKI and from diagnosis were 7.3 months
(95% CI, 2.7 - 13) and 36.7 months (95% CI, 23.6 - 43.9), respectively. No statistical differences in PFS or OS were
observed between gefitinib and erlotinib as the 2
nd EGFR-TKI (PFS, P = 0.23 and OS, P = 0.052). The toxicities
associated with the 2
nd EGFR-TKI were generally acceptable and comparable to those observed for the initial
gefitinib therapy.
Conclusions: Our results indicate that a 2
nd EGFR-TKI treatment can be an effective treatment option for gefitinib
responders.
Background
Gefitinib was the first epidermal growth factor receptor
tyrosine kinase inhibitor (EGFR-TKI) to become available
for the treatment of non-small cell lung cancer (NSCLC).
Several studies have demonstrated that gefitinib is effec-
tive for the second-line treatment of NSCLC [1-3].
Although the phase III ISEL trial failed to prove the
superiority of gefitinib treatment compared to placebo in
previously treated patients, a subgroup analysis demon-
strated improved survival in particular populations
(Asians and non-smokers) [4]. Further analyses in other
studies have also revealed that clinical factors (Asians,
females, non-smokers, and adenocarcinoma histology)
are associated with the response to gefitinib treatment
[5]. EGFR mutations, such as the deletion of exon 19 and
the single L858R mutation in exon 21, have also been
reported to be correlated with a longer survival and were
found more frequently in Asian patients [6-8]. Recently, a
superior progression-free survival (PFS) with gefitinib
compared with the combination of carboplatin and pacli-
taxel in untreated NSCLC patients with predictors of
gefitinib sensitivity was proven in two large phase III stu-
dies [9,10]. Gefitinib is now recommended for advanced
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as a first or a second-line treatment.
Despite the high disease control rate (DCR), gefitinib
treatment is not curative and eventually there is disease
recurrence, even in patients with predictors of sensitiv-
ity. For the many NSCLC patients who previously
responded to gefitinib but later showed tumor progres-
sion, very few treatment options are available.
Some investigators have conducted studies to evaluate
the efficacy of EGFR-TKI re-administration [11-14]. In
most of those studies, both gefitinib responders and
non-responders were retreated with gefitinib or erloti-
nib, and gefitinib responders tended to benefit from the
2
nd EGFR-TKI.
Here, we retrospectively analyzed the efficacy of the
2
nd EGFR-TKI administration after failure of the initial
gefitinib treatment in NSCLC patients who had pre-
viously achieved disease control with gefitinib. The risks
of the 2
nd administration of EGFR-TKI, especially the
association with adverse events in the initial gefitinib
treatment, were also evaluated.
Methods
Patients
We conducted a retrospective search of the medical
records at Niigata University Medical and Dental Hospi-
tal, from June 2005 through October 2009, and we iden-
tified 11 NSCLC patients who had obtained a partial
response (PR) or stable disease (SD) with gefitinib treat-
ment and undergone EGFR-TKI retreatment sometime
after the failure of the initial gefitinib treatment. All
patients were treated initially with oral gefitinib at a
dose of 250 mg/day, which was continued until either a
radiographic tumor or overt clinical progression was
observed. The same dose of gefitinib, or erlotinib at a
dose of 150 mg/day, was used for EGFR-TKI retreat-
ment and continued until tumor progression was
detected.
Assessment of the response and adverse events
The tumor response was evaluated by radiologic exami-
nations according to the Response Evaluation Criteria in
Solid Tumors (RECIST) [15]. Disease control was
defined as complete response (CR), PR or SD. PFS and
overall survival (OS) were defined as the period from
the start of the treatment to the date when disease pro-
gression and death, respectively, were observed.
Adverse events were assessed according to Common
Terminology Criteria for Adverse Events of the National
Cancer Institute (version 3.0) [16].
Statistical analysis
PFS and OS estimates were obtained using the Kaplan-
Meier method.
Results
Patient characteristics
Of the 11 identified patients who benefited from gefiti-
nib and were retreated with EGFR-TKI, 3 patients (27%)
received gefitinib and 8 patients (73%) received erlotinib
as the 2
nd round of EGFR-TKI. As shown in Table 1 the
ages of patients ranged from 46 to 70 years (median, 55
years), and there were 8 females (73%), 7 non-smokers
(64%), and 10 adenocarcinoma patients (91%). Three
patients (27%) exhibited EGFR gene mutations, but the
mutation statuses of the other 8 patients (73%) were not
determined. All patients had received platinum-based
chemotherapy before the initial gefitinib treatment. The
patient characteristics, including treatment backgrounds
and responses, are summarized in Table 2.
Response to the initial gefitinib treatment
During the 1
st EGFR-TKI treatment with gefitinib, 8
patients achieved PR as the best response (73%, Table
3), and 3 patients (27%) were SD. The median PFS was
9.8 months, with a 95% CI of 6.6 to 16.7 months.
Response to the 2
nd EGFR-TKI
Three patients (27%) received the 2
nd EGFR-TKI imme-
diately after gefitinib failure, and 8 (73%) underwent 1
cytotoxic regimen between the initial gefitinib and the
Table 1 Patient Characteristics 1
Characteristics No. of Patients %
Total enrolled 11
Gender
Female 8 73
Male 3 27
Age (y)
Median 55
Range 46-70
ECOG performance status
16 5 5
20 0
33 2 7
42 1 8
Histology
Adenocarcinoma 10 91
Squamous 1 9
Smoking history
Current 3 27
Ex-smoker 1 9
Never 7 64
EGFR mutation
Exon 19 deletion 2 18
L858R 1 9
Not available 8 73
EGFR, epidermal growth factor receptor.
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nd EGFR-TKI treatments. The median interval from the
discontinuation of gefitinib to the 2
nd EGFR-TKI was
2.8 months (95% CI, 1.9 - 6.9, Table 3). Only one
patient (9%) demonstrated PR, 7 (64%) remained SD,
and 3 (27%) had PD. The DCR was 73% (95% CI, 43% -
91%) and the median PFS was 3.4 months (95% CI, 2 -
5.2). The median OS from the beginning of the 2
nd
EGFR-TKI and from diagnosis were 7.3 months (95%
CI, 2.7 - 13.0) and 36.7 months (95% CI, 23.6 - 43.9),
respectively. No statistical differences in PFS or OS were
observed between gefitinib and erlotinib as the 2
nd
EGFR-TKI (PFS, P = 0.23 and OS, P = 0.052).
In contrast with previous studies, we further com-
pared the clinical courses of the patients with those of
gefitinib responders who were not treated with a 2
nd
EGFR-TKI following gefitinib failure. We reviewed the
medical records at our institute and found 9 patients
with backgrounds that were similar to those of the 2
nd
EGFR-TKI patients (sex, age (< 70 years old or > 70
years old), histology, and response to gefitinib treat-
ment). No statistical differences in PFS to 1
st gefitinib
treatment were noted between both groups (9.8
months in the 2
nd TKI group and 8.7 months (95% CI,
7.6 - 9.8) in the control group, P = 0.87). All of the
identified control patients had been treated with plati-
num-doublet chemotherapy before gefitinib but had
not received 2
nd EGFR-TKI. The OS from the start of
the initial gefitinib treatment tended to be longer in
patients who received a 2
nd EGFR-TKI (median OS,
21.5 months (95% CI, 14.6 - 28.4)) compared to those
in the control group (median OS, 12.3 months (95%
CI, 9.4 - 15.2), P = 0.07).
In the control group, 5 out of 9 patients had been
treated with cytotoxic chemotherapy after gefitinib fail-
ure. To compare the efficacy of the 2
nd EGFR-TKI
with chemotherapy after disease progression with gefi-
tinib, data were collected from these 5 patients in the
control group who had received chemotherapy after
gefitinib failure (Table 4). The DCR for chemotherapy
after gefitinib treatment was 20% and comprised one
SD and four PD. The median PFS and OS from the
start of chemotherapy after gefitinib treatment were
only 2 months (95% CI, 1.5 - 2.4) and 2.5 months
(95% CI, 2.2 - 2.8), respectivel y .N os i g n i f i c a n td i f f e r -
ences in the PFS or OS from the start of treatment
after gefitinib were observed between the patients who
received a 2
nd EGFR-TKI and those who underwent
cytotoxic chemotherapy (PFS, P = 0.1 and OS, P =
0.12); however, a 2
nd EGFR-TKI appeared to be a bet-
ter option for gefitinib responders.
Table 2 Patient Characteristics 2
Case Age
(y)
Gender Smoking Histology EGFR
mutation
PFS to
1
st TKI
TKI
sequence
Interval from
1
st and 2
nd
Chemo.
after 1
st
PS Response PFS to
2
nd TKI
OS from
2
nd TKI
1 50 F Current Ad NA 9.8 G®E 7.9 CBDCA
+GEM
1 PD 0.9 13.1
2 46 F Never Ad NA 11.8 G®G 4.5 DOC 1 PR 6.4 24.6
3 58 F Ex Ad 19
deletion
38.4 G®G 2.8 DOC 1 SD 7.3 24.1
4 70 F Never Sq NA 10.2 G®E 12.8 GEM 1 SD 1.7 4.3
5 60 F Never Ad NA 13 G®G 5.4 GEM 1 PD 1.6 2.1
6 63 F Never Ad NA 7.4 G®E 2.6 - 3 SD 3.6 7.8
7 52 M Never Ad L858R 5.8 G®E 1 - 4 SD 6.4 6.4
8 51 M Current Ad NA 4.3 G®E 1.6 AMR 3 PD 0.6 0.9
9 61 F Never Ad NA 8.5 G®E 2.3 VNR 3 SD 2.9 4
10 53 F Never Ad NA 12.9 G®E 0 - 4 SD 6.2 7.3
11 54 M Current Ad 19
deletion
3.8 G®E 7.3 VNR 1 SD 3.2 5
PFS, progression-free survival; TKI, tyrosine kinase inhibitor; PS, performance status; OS, overall survival; F, female; M, male; Ex, ex-smoker; Ad, adenocarcinoma;
Sq, squamous cell carcinoma; G, gefitinib; E, erlotinib; CBDCA, carboplatin; GEM, gemcitabine; DOC, docetaxel; AMR, amrubicin; VNR, vinorelbine; PR, partial
response; SD, stable disease; PD, progressive disease.
Table 3 Summary of prior therapy
Characteristics No. of patients %
No. of chemotherapy regimens before gefitinib
12 1 8
24 3 6
34 3 6
41 9
Best response to gefitinib
PR 8 73
SD 3 27
PFS to gefitinib
Median 9.8
95% CI 6.6 - 16.7
Interval from discontinuation of gefitinib to 2
nd EGFR-TKI
Median 2.8
95% CI 1.9 - 6.9
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treatments
To determine whether the initial gefitinib treatment and
EGFR-TKI retreatment caused similar adverse events,
we assessed the toxicity profiles of all 11 patients (Table
5). The most common toxicity associated with both
treatments was a grade 1/2 skin rash. Although one
patient presented a grade 3 elevation of g-glutamyltran-
speptidase during both treatment with gefitinib and with
erlotinib (patient no. 7), the other observed toxicities
were generally acceptable. In 5 patients, the toxicity pro-
files for the initial gefitinib and the 2
nd EGFR-TKI treat-
ments were similar. None of thep a t i e n t sd e m o n s t r a t e d
interstitial lung disease in response to EGFR-TKI.
Discussion
To the best of our knowledge, 18 cases of patients who
received gefitinib re-administration after failure of the
initial gefitinib treatment have been reported to date,
including 3 cases reported by our group (Table 6)
[17-21]. All 18 patients responded to the initial gefitinib
treatment, and most of the cases underwent cytotoxic
chemotherapy between the first and second gefitinib
therapy. Fourteen patients benefited from the 2
nd gefiti-
nib treatment, and the overall DCR was 78%. In our 3
patients, the toxicity of the 2
nd gefitinib was similar to
that observed for the initial gefitinib treatment and was
acceptable. Gefitinib retreatment is likely a good option
for patients who have demonstrated a response to a pre-
vious gefitinib treatment.
Clinical studies have demonstrated that erlotinib is
effective even in patients who are not considered to be
good responders to gefitinib, such as those with a nega-
tive EGFR mutation, squamous cell carcinoma, or a his-
tory of smoking [22]. Because erlotinib is used at its
maximum tolerated dose, whereas gefitinib is used at
only about one-third of its maximum tolerated dose in
daily practice, the biological activity of erlotinib at stan-
dard doses may be higher than that of gefitinib
[2,4,23-25]. These reports suggest that erlotinib may be
active even in patients who demonstrated tumor pro-
gression during a prior gefitinib treatment. Thus, erloti-
nib has been selected as a treatment option for use after
gefitinib failure (Table 7) [11-14,26-33]. In most studies,
including the present investigation, favorable results
have been documented, and the authors have concluded
that erlotinib appears to be a useful treatment after gefi-
tinib failure.
Although it is difficult to address the precise mechan-
ism underlying these results, several studies have sug-
gested a possible explanation for the clinical benefit of
EGFR-TKI retreatment. Some cytotoxic agents have
been reported to restore the sensitivity of NSCLC cells
to gefitinib in vitro by increasing EGFR phosphorylation
[34,35]. It is also possible that chemotherapy during the
EGFR-TKI-free interval could decrease EGFR-TKI resis-
tant tumor cells. However, no significant differences in
PFS or OS were observed between our patients who
received chemotherapy before the 2
nd EGFR-TKI and
those who received the 2
nd EGFR-TKI immediately after
gefitinib failure. In addition, the duration between the
initial gefitinib and the 2
nd EGFR-TKI treatments was
not associated with the response to 2
nd EGFR-TKI.
Similarly to these findings, other researchers have found
no evidence that either chemotherapy among the 1
st
and 2
nd EGFR-TKIs or the duration of the EGFR-TKI-
free period affects either PFS or OS in the 2
nd EGFR-
TKI [31,33].
Secondary EGFR mutations might be associated with
t h ee f f i c a c yo fe r l o t i n i ba f ter gefitinib failure. MET
amplification and secondaryE G F Rm u t a t i o n s ,s u c ha s
Table 4 Tumor response to 2nd EGFR-TKI vs.
chemotherapy
Characteristics 2
nd TKI group Control group P
OS from 1
st gefitinib
Median 21.5 12.3 0.07
95% CI 14.6 - 28.4 9.4 - 15.2
Response to 2
nd TKI or chemotherapy
PR 1 0
SD 7 1
PD 3 4
PFS to 2
nd TKI or chemotherapy
Median 3.4 2 0.1
95% CI 2 - 5.2 1.5 - 2.4
OS from 2
nd TKI or chemotherapy
Median 7.3 2.2 0.12
95% CI 2.7 - 13 2.2 - 2.8
Table 5 Toxicity profiles for the initial gefitinib and 2nd
EGFR-TKI treatments. Adverse events were evaluated
according to Common Terminology Criteria for Adverse
Events of the National Cancer Institute (version 3.0).
Case Initial gefitinib 2
nd EGFR-TKI
1 - Rash G2
2 Rash G2 -
3- -
4 Rash G2, Liver G1, Diarrhea G2 Rash G1, Diarrhea G1
5 Rash G1 Rash G2
6 Diarrhea G2, Taste alteration G2 Rash G1, Diarrhea G1
7 Rash G2, Liver G3 Rash G2, Liver G3
8 Rash G2 Liver G2
9 Rash G1, Nail G1, Nausea G1 Rash G1
10 Liver G1 -
11 - Rash G1, Diarrhea G1
G, grade; Liver, serum glutamic pyruvic transminase, serum glutamic
oxaloacetic transaminase and g-glutamyltranspeptidase.
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Page 4 of 7T790 M, L747 S, D761Y, and T854A have been identi-
fied in NSCLC patients with an acquired resistance to
EGFR-TKI [36-42]. T790 M mutation was found in
50%, MET amplification in 20%, and other secondary
mutations in less than 5% of the NSCLC patients carry-
ing EGFR mutations with TKI resistance [43,44]. In
vitro studies have revealed that tumor cells carrying
non-T790 M mutations show a partial resistance to
EGFR-TKI, but are much less resistant compared to
cells with T790 M. These data suggest that an increased
EGFR-TKI dose might circumvent the acquired resis-
tance caused by non-T790 M mutations. Previous stu-
dies have indicated that the serum concentration of
erlotinib is several-fold higher than that of gefitinib at
standard doses [24,25]. This difference in biological
activities between the TKIs may contribute to the effi-
cacy of erlotinib after gefitinib failure in patients carry-
ing non-T790 M mutations.
In conclusion, our findings suggest that a 2
nd EGFR-
TKI can be a treatment option for patients who benefited
from a previous gefitinib treatment. However, as shown
in Table 7 some studies failed to demonstrate the efficacy
of 2
nd EGFR-TKI after gefitinib failure. Cho et al. men-
tioned that the tumor response to 1
st gefitinib treatment
c a nb eap r e d i c t i v em a r k e r[ 1 4 ] .T h e yd e s c r i b e dt h a t
patients who showed SD during 1
st gefitinib treatment
had better survival with 2
nd EGFR-TKI, however those
who had PD to 1
st gefitinib rarely responded to 2
nd
EGFR-TKI. The difference in the percentage of patients
w i t hag o o dp r e d i c t o rm i g h ta f f e c tt h er e s u l t so ft h e s e
trials about 2
nd EGFR-TKI. Intense research has been
devoted to clarifying the mechanism responsible for
acquired resistance, but it is difficult to obtain clinical
samples from all patients to confirm MET amplification
or secondary mutations. Jackman et al. recently published
a clinical definition of acquired resistance to EGFR-TKI
[45]. This consensus definition will facilitate the estab-
lishment of standard entry criteria for studies investigat-
ing acquired resistance. All of our patients except one
met these criteria (no. 8 in Table 2). Despite rapid tumor
progression during a previous cytotoxic chemotherapy,
this patient obtained SD with an initial gefitinib therapy
of 4.3 months, and therefore we considered this patient
to have benefited from the gefitinib treatment. Further
clinical trials are required to develop a novel treatment
for patients with acquired resistance.
Conclusion
In the current study, we analyzed the efficacy and toxicity
of a 2
nd EGFR-TKI treatment in patients who demon-
strated a response to prior gefitinib therapy and tumor
progression. A second EGFR-TKI treatment was generally
effective in patients who had benefited from the initial
gefitinib therapy. The adverse events associated with a 2
nd
EGFR-TKI were acceptable and comparable with those
observed for the initial gefitinib therapy. In Japan, gefitinib
has been approved for the treatment of inoperable and
recurrent NSCLC since 2002, and many patients have
already experienced a need for a new treatment option fol-
lowing gefitinib treatment. Based on the present data, a
2
nd EGFR-TKI treatment could represent a potentially
new treatment for gefitinib responders. Prospective clinical
trials and translational analyses in this area of research are
warranted.
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